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Rapamycin has been found by multiple laboratories to 
extend mouse lifespan even when mice began receiving 
rapamycin relatively late in life at 20 months of age, or 
roughly the equivalent of 55 human years [1].  In 
addition, rapamycin has been shown to delay the onset 
of  several  age-related diseases,  including  Alzheimer’s  
 
 













































disease, cardiovascular disease, and cancer in mouse 
models of these pathologies [2-5]. These findings have 
led to significant interest in the potential effects of 
rapamycin as an anti-aging intervention in humans 
particularly because rapamycin is already approved for 
use in cancer therapy and as an adjunct immuno-
suppressive agent for transplant patients.  























Abstract  Rapamycin  has  been  shown  to  extend  lifespan  in  rodent models,  but  the  effects  on metabolic  health  and
function have been widely debated in both clinical and translational trials. Prior to rapamycin being used as a treatment to
extend both  lifespan and healthspan  in  the human population,  it  is vital  to assess  the  side effects of  the  treatment on
metabolic pathways  in animal model  systems,  including a closely  related non‐human primate model.    In  this  study, we
found  that  long‐term  treatment of marmoset monkeys with orally‐administered encapsulated  rapamycin  resulted  in no
overall effects on body weight and only a small decrease in fat mass over the first few months of treatment. Rapamycin
treated  subjects  showed  no  overall  changes  in  daily  activity  counts,  blood  lipids,  or  significant  changes  in  glucose
metabolism  including oral  glucose  tolerance.   Adipose  tissue displayed no differences  in  gene  expression of metabolic
markers following treatment, while liver tissue exhibited suppressed G6Pase activity with increased PCK and GPI activity.
Overall, the marmosets revealed only minor metabolic consequences of chronic treatment with rapamycin and this adds to
the growing body of  literature  that  suggests  that  chronic and/or  intermittent  rapamycin  treatment  results  in  improved
health  span  and  metabolic  functioning.  The  marmosets  offer  an  interesting  alternative  animal  model  for  future
intervention testing and translational modeling. 
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However, clinical administration of rapamycin has the 
potential for several side-effects include hyperlipidemia 
and hyperglycemia [6], raising concerns as to the 
potential negative impacts of rapamycin exposure in 
aged human populations that may have a high 
underlying prevalence of obesity- and age-induced 
insulin resistance and hyperlipidemia.   However, 
results from clinical populations suggests that some side 
effects, such as hypertriglyceridemia, may improve over 
time and that others may be dose-dependent [6]. The 
nature of the human data accumulated thus far paints a 
far from complete picture of why and how rapamycin 
might affect metabolism and lipid trafficking. 
Moreover, these clinical studies have focused on 
patients with pre-existing conditions and have largely 
utilized combination therapies with other 
immunosupressants or steroids that can cause metabolic 
dysfunctions of their own [7]. There have, however, 
been no long-term studies of the effects of 
monothereapy with rapamycin or its analogs in 
populations of otherwise healthy humans. Thus, it is not 
clear whether the previously reported metabolic risks of 
rapamycin and its analogs are due to this drug directly 
or to other confounding factors. 
 
In rodent models, monotherapy with rapamycin has 
largely, though not equivocally, been associated with 
impairment of glucose metabolism as measured in 
glucose tolerance tests. A notable exception is a study 
by Fang et al. suggesting that chronic treatment with 
rapamycin has a biphasic effect on glucose metabolism 
with short-term rapamycin treatment being detrimental 
to glucose metabolism whereas long-term (20 wk) 
treatment with rapamycin may promote an insulin-
sensitive state in mice with a transition state in between 
[8].  Further examination has revealed that long term 
treatment of rapamycin leads to a metabolic switch 
resulting in enhanced insulin signaling and better 
triglyceride processing [9]. These rodent studies have 
largely been performed in animals maintained on a 
relatively standardized rodent chow, though there is 
evidence that rapamycin has similar effects on both 
lifespan and metabolic function in mice fed diets high in 
caloric content due to increased levels of sugar and/or 
fat [10,11]. Mice given intermittent treatment of 
rapamycin and placed on a high fat diet have no gross 
changes in metabolic markers, and rapa appears to 
prevent weight gain [12]. Combining the intervention 
therapies of rapamycin and resveratrol treatment in 
mice was found to prevent insulin resistance in mice 
being fed a high fat diet and suggests that combination 
therapy may be beneficial in a high fat environment 
[13].  Human glucose metabolism is regulated by a 
complex interaction of genetics and environment 
(including diet) that cannot be fully recapitulated in 
laboratory rodents [14]. Even the timing of or causes of 
eating/overeating differ between rodent models and 
humans, further complicating this issue [15, 16]. At the 
molecular level, there are significant discrepancies 
between rodents and humans in alterations of gene 
regulation in metabolic dysfunction suggesting there is 
little overlap between the two models [17]. Lastly, 
many of the complications of metabolic dysfunction 
including nephropathy, neuropathy, and cardiac 
dysfunction cannot be successfully replicated in single 
genetic mouse models of metabolic dysfunction or in 
high fat-fed rodents [18]. Thus, a significant question 
remains whether the choice of diet (as well as sex of 
animals or background genetics) could potentially 
complicate the potential for translation [19-21]. An 
approach to address whether the effects (and potential 
side-effects like metabolic dysfunction) of rapamycin in 
otherwise healthy rodents may also be relevant to 
humans is to perform such experiments in other 
species that are predicted to have similar phenotypic 
metabolic regulation as humans. In other words, 
studies of rapamycin’s effects in a species more 
closely related to humans can inform as to the 
generalizability of the rodent findings and issues likely 
to impede the general use of rapamycin as an anti-
aging treatment in humans.   
 
The common marmoset (Callithrix jacchus) is a small 
monkey with a relatively short lifespan.  Both its small 
size and associated shorter lifespan make this species a 
valuable nonhuman primate model for the study of 
aging and chronic disease [22, 23]. Captive marmosets 
display many similarities to humans in terms of obesity 
and its sequelae. Spontaneous obesity has been 
described in multiple captive marmoset colonies that are 
socially housed and fed a relatively low fat, high fiber 
diet [22, 24-28]. Obesity in marmosets, defined in a 
fashion similar to that used in humans, is statistically 
associated with increased risk to metabolic dysfunction 
and cardiovascular disease [16]. In addition to 
displaying evidence of insulin resistance, marmosets at 
extremely high weights (over 500 grams) show higher 
age-specific mortality rates as adults when compared to 
animals of average weight [22]. From 2010-2011, we 
conducted a year-long study of daily dosing of a group 
of common marmosets with rapamycin. We previously 
reported that we were able to maintain circulating blood 
levels of rapamycin at 5.2 ng/mL by giving the animals 
a dose of eudragit encapsulated rapamycin in yogurt of 
1mg/kg/day.  Subjects demonstrated a decrease in 
mTORC1 after two weeks of treatment.  There was no 
evidence of clinical anemia, mouth ulcers, lung fibrotic 
changes, significant changes in wound healing, or 
increased mortality [29]. This report describes a set of 
metabolic outcomes from this study.   
  





Rapamycin treated subjects displayed a significant loss 
of body fat mass at two months post-dosing while 
control subjects displayed a statistically insignificant 
change in body fat mass, as illustrated in Fig. 1A 
(treatment x time interaction, p < 0.0097; difference in 
month 0 and month 2 mean for rapamycin treated 






































The rapamycin treated subjects had significantly 
reduced body fat mass in months 2, 3 and 5, after which 
their mean fat mass did not differ from the pre-dosing 
mean (treatment effect, F=5.385, p=0.018, Dunnett’s 
multiple comparison test significant, p < 0.05, for 
month 0 versus months 2, 3, and 5), resulting in no 
difference between control and rapamycin treated 
subjects at the end of the study as illustrated in Fig. 1B. 
There were no significant differences between controls 
and rapamycin treated subjects and no effects of 
rapamycin treated subjects over time on body lean 
mass. 
 
Food intake and activity levels 
 
There were no significant differences between controls 
and rapamycin treated subjects in food intake at two 
months post-dosing.  In rapamycin-treated marmosets, 
there was a significant increase in food intake at month 
5, over the pre-dosing food intake (treatment effect, 
F=8.353, p=0.001, Dunnett’s multiple comparison test 
significant, p < 0.05, for month 0 versus month 5), as 























In both control and rapamycin-treated subjects activity 
scored as accelerometer counts per hour declined 
significantly after the second month of dosing, as 
illustrated in Fig. 3, then remained stable over the 
remainder of the study. There were no significant 
differences between controls and rapamycin treated 
subjects. Because both groups were affected, these data 
suggest that this decline was a result of habituation to 
wearing the harness holding the accelerometer.   
 
Lipid and glucose metabolic measures 
 
There were no significant differences between controls 
and rapamycin-treated subjects in pre- versus post-
dosing mean circulating triglyceride concentrations.   
 
Figure 1. Change in fat mass. (A) Change in fat mass at 1 and





in  fat mass  from pre‐dosing measurement  for months 1‐11  for
rapamycin  subjects.  *  treatment  effect,  F=5.385,  p=0.018,
Dunnett’s  multiple  comparison  test  significant,  p  <  0.05,  for
month 0 versus months 2, 3, and 5. 
Figure 2. Food  intake. Daily dry matter  intake  for months 0‐
12, month  0  is  a  pre‐dosing measurement.  Squares  =  control 
subjects;  triangles  =  rapamycin  subjects  (mean  +  SD).  * 
treatment  effect,  F=8.353,  p=0.001,  Dunnett’s  multiple 
comparison test significant, p < 0.05, for month 0 versus month 5. 
  


















There was, however considerable inter-individual 
variation in both baseline triglyceride concentration and 
in change over time, as illustrated in Fig. 4.  Two of the 
rapamycin treated subjects that were borderline 
hypertriglyceridemic (476 and 402 mg/dl, with > 400 
mg/dl defined as hypertriglyceridemic, [24] before 
dosing, displayed dramatic increases in circulating 
triglyceride concentration at month 2 (702 and 1,359 
mg/dl); however, their triglyceride concentrations then 
varied considerably over the next 7 months.  There was 
no consistent hypertriglyceridemia caused  by 
rapamycin among subjects who began with normal 
circulating triglyceride concentrations There were two 
subjects (one control and one rapamycin treated) that 
displayed severe hypertriglycerimedia before dosing 
(603 and 1,611 mg/dl respectively).  They both 





















Three measures of glucose metabolic function were 
assessed: fasting blood glucose, QuickI index, and 
AUC. There were no significant changes in fasting 
glucose concentrations as illustrated in Fig. 5A. The 
QuickI index, calculated as 1/[log(fasting insulin) + 
log(fasting glucose)], is the typical measure reported in 
nonhuman primate studies to provide an estimate of 
insulin sensitivity, with higher values indicating more 
insulin sensitivity.  The area under the curve (AUC) for 
the glucose tolerance tests represents the relative 
glucose excursion caused by a consistent dose of 
glucose and is a measure of the efficiency with which 
the entire system can remove glucose from the 
circulation.  As illustrated in Fig. 5D, the mean QuickI 
index for the control group was higher than that for the 
rapamycin treated group prior to treatment (F=5.396, p 
= 0.0453, Sidak’s multiple comparison test, p < 0.05 for 
month 0 control vs rapamycin treated), suggesting that 
the animals that became the control group were, on 
average, more insulin sensitive than those in the group 
randomly selected to be treated with rapamycin.  
However, the rapamycin-treated group displayed a 
reduced QuickI measurement even prior to treatment 
that was not altered during these first two months of 
dosing as indicated by the lack of a significant 
interaction effect. We also found that QuickI did not 
differ among rapamycin-treated animals through 8 
months of rapamycin treatment as illustrated in Fig. 5C. 
There were no differences between control and 
rapamycin treated subjects and no interaction effect on 
the glucose AUC.  There were also no significant 
differences in post-dosing average glucose AUC in the 
rapamycin treated subjects through 8 months of dosing, 
as illustrated in Fig. 5B. Together, these data suggest 
limited to no impairment of glucose metabolism in 
healthy marmosets treated with daily administration of 
rapamycin at doses sufficient to reduce mTOR 
signaling. 
 
Assessment of molecular effects 
 
The long-term administration of rapamycin in rodents 
has been associated with hyperglycemia caused in part 
by increased gluconeogenesis [27-29]. In the liver of 
rapamycin treated animals, we found significant 
upregulation of the expression of phosphoenolpyruvate 
carboxykinase (PCK1), indicative of altered gluconeo-
genic capacity. Surprisingly, we found that glucose 6 
phosphatase expression in rapamycin treated animals 
was significantly reduced (Fig. 6). Rapamycin did not 
alter the expression of other markers of 
gluconeogenesis.  The lack of a consistent alteration in 
the expression of gluconeogenic effectors may explain 
why rapamycin-treated marmosets showed no 
significant change in fasting blood glucose levels. 
Fiure  3.  Daily  activity.  Accelerometer  counts  per  hour  for
months  2‐13  of  dosing.  Squares  =  control  subjects;  triangles=
rapamycin subjects (mean + SD).  
 
Figure  4.  Circulating  triglyceride.  Circulating  triglyceride
concentrations  for  each  rapamycin  subject  for  months  0‐6,
month 0 is a pre‐dosing measurement.  The solid horizontal line
represents  the  previously  established  cut‐off  point  for  normal
triglyceride concentrations in this species. 
  


























































































Because rapamycin modulated fat content of marmosets 
in the early periods of treatment, we assessed the 
potential modulation of  effectors  of  lipolysis/lipogene- 
sis in adipose. In visceral adipose samples, we found no 
significant effects on the phosphorylation or expression 
of any of these markers, suggesting little effect of 
rapamycin. However, at the time of sacrifice, 
rapamycin-treated marmosets were not significantly 
leaner than control animals. Due to limitations of the 
design of this study, we could not determine whether 
these effectors were altered by rapamycin at earlier time 














Figure  6.  Immunoblot  results.  Immunoblot  results  for  the  following:
adipose  triglyceride  lipase  (ATGL),  pyruvate  carboxylase  (PCB),  glucose‐6‐
phosphatase  α  (G6Pase),  glucose‐6‐phosphate  isomerase  (GPI),  peroxisome
proliferator‐activated  receptor  γ  (PPARγ),  phospho‐pyruvate  dehydrogenase
kinase  (p‐PDK1),  pyruvate  dehydrogenase  kinase  (PDK1),  phosphoenol‐
pyruvate carboxykinase 1 (PCK1), sterol regulatory element‐binding protein 1
(SREBP1) corrected by actin.  A. Adipose tissue collected at sacrifice following
14 months of rapamycin  (black) or control dosing  (grey)  (mean + SE) B. Liver
tissue  collected  at  sacrifice  following  14  months  of  rapamycin  (black)  or
control dosing (grey) (mean + SE) *indicates significance p<0.05. 
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DISCUSSION 
 
Prior to assessing the effectiveness of rapamycin as an 
anti-aging treatment in humans, it is first necessary to 
elucidate the potential effects on long term health 
outcomes.  In particular, there has been a great deal of 
controversy and inconsistent results in the clinical 
studies of rapamycin, which have highlighted the 
potential increased risk for metabolic defects such as 
hyperlipidemia and hyperglycemia that are consistent 
with increasing risk of cardiovascular disease and type 2 
diabetes [30]. However, the effects of this drug on 
relatively healthy humans are largely unknown. A 
recent short term study (6 weeks) of elderly patients 
given doses of a rapamycin analog found few side 
effects significant from placebo control subjects and 
reported a significant increase in serological response to 
flu vaccination, however, this study did not examine 
any markers of metabolic health in these subjects during 
treatment [31].  In order to assess potential 
consequences of long term rapamycin treatment on 
primate metabolic health we tested the effects of 
rapamycin on a group of healthy, aged, non-human 
primates, the common marmoset.  We previously 
reported the ability to reliably and routinely dose 
socially housed marmoset monkeys with yogurt 
mixtures containing eudragit encapsulated rapamycin 
[29]. Dosing with 0.4 mg/day resulted in average blood 
rapamycin levels of 5.2 ng/mL, which is well within the 
range found in studies of other model species, and 
humans [1-5].  Further, we previously reported evidence 
of suppressed phospho-rpS6 in PBMC samples of 
rapamycin subjects suggesting down-regulation in 
mTORC1.  In this study we reported several markers 
that suggest that chronic oral dosing with eudragit-
encapsulated rapamycin has little impact on the 
metabolic status of marmosets. 
 
Many have proposed that rapamycin is a mimic of 
calorie restriction which is the gold-standard for anti-
aging intervention resulting in both extended life span 
and health span in many rodent models.  Rapamycin has 
been shown to suppress mTOR activity, potentially 
decrease weight and fat mass, and extend healthspan 
and life span in a similar manner as calorie restriction 
[1-4].  In marmosets we demonstrated no overall change 
in body weight while being treated with rapamycin, but 
the marmosets did have significant loss of body fat.  
However, the loss of body fat stabilized at 
approximately five months of treatment and this time 
point was associated with an increase in food intake of 
rapamycin subjects.   While we are unable to elucidate 
the underlying mechanisms for the sudden shift in 
dietary intake at 5 months of dosing, it is interesting to 
consider the possibility that the rapamycin-dosed 
animals altered caloric intake in response to the fat mass 
loss [32].  
 
One of the major reported risks of rapamycin 
administration clinically is the development of new-
onset type 2 diabetes as shown in clinical studies of 
kidney transplant patients treated with rapamycin 
analogs [33, 34]. However, the interpretation of these 
data is complicated by several factors including the 
impaired health status of the subjects and the use of 
combination therapies using additional drugs that are 
known to cause metabolic impairment on their own. 
Recent clinical studies of kidney transplant patients 
suggest that Tacrolimus rather than Sirolimus may be 
the leading cause of new onset diabetes within 10 weeks 
of treatment, however all research suggests that 
continued examination of monotherapies are needed to 
elucidate the side effects of each immunosuppressant 
[35, 36].  In rodents, the chronic administration of 
rapamycin as a mono-therapy has often been shown to 
impair glucose metabolism. For example, both inbred 
and genetically heterogeneous mouse strains develop 
glucose intolerance with oral administration of 
encapsulated rapamycin [11, 37, 38]. In inbred 
C57BL/6 mice, but not genetically heterogeneous mice, 
rapamycin is also associated with the development of 
insulin resistance.  Interestingly, these effects of 
rapamycin on metabolism are dependent on both dose 
of rapamycin and sex of subjects [38] and do not appear 
to be permanent alterations as the metabolic defects can 
be reversed by ending rapamycin treatment [11]. 
Similarly, rapamycin treatment to normoglycemic, pre-
diabetic P. obesus treated with rapamycin display 
heightened hyperglycemia and increased insulin 
resistance in part by reducing pancreatic β-cell function.  
In this rodent model it was suggested that rapamycin 
exacerbated the pre-existing diabetic symptoms and 
metabolic disorder in high risk animals [39]. 
Alternatively the effect of rapamycin is thought to 
mimic the metabolic changes associated with starvation 
diabetes or Type 0 diabetes [40, 41, 42]; which is often 
thought to be a positive, adaptive form of metabolic 
changes associated with enhanced metabolic efficiency 
and decreased risk of true diabetes.  Evidence of 
enhanced insulin signaling following long term rapa [9], 
and intermittent rapa [11], as well as little evidence for 
detrimental mitochondrial function following rapamycin 
[42], supports the hypothesis that rapamycin may in fact 
be inducing changes similar to starvation diabetes [13, 
40-42].  Interestingly, in our current study we found no 
evidence that rapamycin negatively impairs glucose 
metabolism in marmosets. One possible interpretation 
of these findings could be that rapamycin treatment 
might negatively and significantly affect only subjects 
that are predisposed to metabolic disease. This also 
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might explain some of the slight differences in 
rapamycin’s effect on glucose metabolic dysfunction in 
C57BL/6 but not genetically mixed mice. Another 
possible explanation could be the length of treatment 
utilized here. Recent studies have suggested a bi-phasic 
effect of rapamycin on glucose metabolism, with long-
term administration of rapamycin to mice associated 
with increased, rather than reduced insulin sensitivity 
[8, 9, 44]. However, others have shown rapamycin in 
eudragit-encapsulated form (as we used in this study) 
does not show this bi-phasic effect, but rather 
continuously impairs glucose metabolism in mice 
[11,37]. In part, the metabolic impairments of 
rapamycin are thought to be due to inhibition of 
mTORC2 rather than mTORC1 [45]; while we 
previously showed that this rapamycin dose was 
sufficient to inhibit mTORC1 [29], it may not be 
sufficient to inhibit mTORC2 signaling in the marmoset 
and thus minimize the presumed metabolic defects of 
rapamycin treatment.  
 
The increased risk of hyperglycemia with rapamycin 
treatment has been attributed to increased hepatic 
gluconeogenesis in rodent studies. In both mice and rats, 
rapamycin treatment significantly increases hepatic 
glucose production following injection with pyruvate and 
increases the expression of the gluconeogenic effectors 
like PCK1 and G6Pase [45, 46]. In this study, we also 
confirmed that a significant increase in PCK1 with 
rapamycin treatment, but paradoxically, found a 
significant decrease in G6Pase. While the rise in PCK1 
would be consistent with increased gluconeogenesis, the 
decrease in G6Pase might be interpreted as inhibiting this 
process. It is not clear why rapamycin treatment has this 
contrasting effect in marmosets, but this might explain 
why marmosets did not display hyperglycemia with this 
treatment.  
 
In addition to its well-known roles in cell survival and 
growth, recent studies have linked the mTOR signaling 
pathway with the regulation of lipid metabolism [47]. 
However, the direct effects of rapamycin on lipid 
metabolism have often been contradictory in published 
reports. For example, rapamycin has been reported to 
both improve and impair fatty acid oxidation in skeletal 
muscle cell lines [44, 48]. Reports regarding 
rapamycin’s effects on lipid utilization in vivo in 
rodents are similarly inconsistent; rapamycin has been 
reported to decrease, increase or not effect fat 
accumulation among several different studies [1, 11, 37, 
38, 49, 50]. Here, we found that rapamycin significantly 
reduced fat mass in marmosets at early time points in 
our treatment regime. However, after approximately 5 
months of treatment,  fat  mass  no  longer  differed  bet- 
ween rapamycin-treated and control marmosets and we 
found no evidence for differences in lipolysis or 
lipogenesis in adipose tissue collected at the end of this 
study. Interestingly, this change coincided with a 
significant increase in food consumption among the 
rapamycin-treated marmosets. This alteration could 
represent a compensatory effect for the long-term 
inhibition of mTOR signaling. Further temporal studies 
regarding the effect of rapamycin in this model will be 
necessary to address this possibility. 
 
Treatment with rapamycin as an intervention in the 
aging process for humans offers many possibilities but 
some studies have reported deleterious side effects that 
raise concern regarding the efficacy of this treatment.  
This study represents the first to examine the metabolic 
consequences of rapamycin dosing in healthy non-
human primates.  We have reported here evidence that 
long term rapamycin treatment at a dose that has been 
used in previous studies and reduces mTOR signaling in 
marmosets [29] does not result in notable negative side-
effects on metabolic function in healthy marmosets. We 
believe that marmosets offer a unique non-human 
primate model that will allow detailed evaluation of the 
effect of potential anti-aging treatments on primate 
metabolic function, dietary intake, and activity 
patterning. 
 
MATERIALS AND METHODS 
 
Subjects. The subjects for this study were common 
marmosets (Callithrix jacchus) housed at the Southwest 
National Primate Research Center. Basic husbandry and 
housing for this colony have been described previously 
[51]. Thirteen subjects between the ages of 7.1 and 9.1 
years were housed as female-vasectomized male pairs. 
Four pairs received daily oral dosing of 1.0 mg/kg/day 
(0.40 mg/day) rapamycin in a yogurt vehicle via syringe 
for 14 months as described [29]. Two pairs (5 subjects, 
one male died mid-way through the study and was 
replaced with another male) received daily doses of 
empty eudragit capsules in yogurt as control. 
Throughout the long term dosing regimen several 
markers of metabolic health were assessed. 
 
Body composition: Marmoset lean and fat mass was 
assessed monthly via quantitative magnetic resonance 
(QMR) imaging using an Echo MRI unit [26]. 
Unsedated animals were placed in a plastic tube which 
was then inserted into the magnetic chamber with scans 
taking less than 2 minutes on average for each animal.  
Animals were weighed biweekly throughout the project 
by placing a scale within the cage and rewarding the 
animal’s for maintaining position on the scale.  
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Caloric intake. Subjects participated in a 2 day food 
intake trial once per month for the length of the trial 
[28]. For these trials the subjects were separated from 
each other within the cage and fed their daily base diet 
consisting of two feed types from Harlan Teklad and 
Purina. Samples of each diet were taken from each 
prepared batch, frozen and stored until analysis. Diet 
fed to the subjects was weighed prior to feeding. After 
24 hours all remaining food was removed and weighed, 
and fresh food was weighed and fed. After 48 hours all 
remaining food was removed and weighed and the 
subjects were returned to normal housing and feeding 
schedule. Samples were dried and dry weight 
consumption and caloric consumption was calculated 
and averaged over the 48 hour period. 
 
Activity. Daily activity patterns were assessed with the 
Mini actiwatch (CamNtech) which were placed in a 
marmoset pouch (Lomar) on a ferret harness (Petco). 
Subjects were gradually habituated to the ferret 
harnesses over the course of three weeks, increasing 
time in the harness incrementally throughout training 
until 24 hours in the harness had been achieved. The 
miniwatches are data loggers that batch data in 15 
second epochs. For these trials animals were separated 
from each other within the cage and placed in harnesses 
with the actiwatch in the pouch secured across the back 
of the animal. Animals remained in the harness for 48 
hours of data collection during which normal husbandry 
and feeding continued. At the end of the trial the 
animals were captured in transfer boxes and the 
harnesses were removed. Data was downloaded from 
the device. The activity counts from the first 15 minutes 
and last 15 minutes of the collection were removed 
from analysis as these represented handling and cage 
manipulation. 
 
Blood chemistry. Each month animals were fasted 
overnight and 2 ml of blood were drawn to assess 
circulating triglyceride concentrations, fasting glucose 
and insulin concentrations. Fasting glucose was 
determined immediately following the blood collection 
via glucometer.  Blood was collected into serum 
separator tubes, spun and frozen in -80°C until further 
analysis.  Triglyceride concentrations were assessed at 
the SNPRC clinical pathology lab. Samples were 
shipped to Wisconsin for analysis of insulin 
concentrations as described [52]. 
 
Glucose challenge. Animals were fasted overnight prior 
to an oral glucose tolerance test [24], and placed in a 
restraint device used for blood collection to which they 
had previously been habituated. An EDTA coated 
needle and syringe were used to collect 0.5 ml of blood 
from the femoral vein for the baseline bleed. The 
animals were then dosed orally with a 40% dextrose 
solution receiving a calculated glucose dose equal to 
0.5% of their current body weight.  Subjects remained 
in the restraint for a 15 and 30 minute post dose blood 
sample drawn from the tail vein via an EDTA coated 
butterfly needle. Subjects were removed from the 
restraint device following the 30 minute sample and 
placed in a transport box until the 60 minute sample, 
and this was repeated for the 120 minute sample.  The 
15, 60 and 120 minute samples were glucometer reads 
only. For the 30 minute sample 0.5 ml of blood was 
collected for further analysis. Following the 120 minute 
bleed the animals were returned to their home cage and 
fed.  The 0 and 30 minute samples were spun and frozen 
until shipment to Wisconsin for insulin assay analysis. 
 
Immunoblots. Total protein extracts were isolated from 
liver and visceral fat tissue that had been snapped 
frozen in liquid nitrogen after sacrifice and stored at -
80°C until use. Protein extracts were homogenized in 
RIPA buffer with additional protease and phosphatase 
inhibitors (Thermo Scientific, Rockford, IL, USA), 
centrifuged at 14,000g at 4°C for 15 minutes, and then 
stored at  -80°C until needed.  Equal amounts of protein 
samples were separated electrophoretically by SDS-
PAGE and then transferred to polyvinylidene difluoride 
membrane (Millipore, Billerica, MA, USA). Primary 
antibodies and their sources used in this study: adipose 
triglyceride lipase (ATGL), pyruvate carboxylase 
(PCB), glucose-6-phosphatase α (G6Pase), glucose-6-
phosphate isomerase (GPI), and actin from Santa Cruz 
(Santa Cruz CA), peroxisome proliferator-activated 
receptor γ (PPARγ), phospho-pyruvate dehydrogenase 
kinase (p-PDK1), pyruvate dehydrogenase kinase 
(PDK1), phosphoenolpyruvate carboxykinase 1 (PCK1) 
from Cell Signaling (Beverly MA), sterol regulatory 
element-binding protein 1 (SREBP1) from Abcam 
(Cambridge MA) and deptor from Millipore with all 
alkaline phosphatase-conjugated secondary antibodies 
(anti-rabbit and anti-mouse) from Santa Cruz. Protein 
bands on immunoblots were detected using ECL 
reagent and analyzed using ImageJ. 
 
Analyses. Variables of interest included body mass, fat 
mass, fat-free mass, 24 hour total actimeter counts, 24 
hour caloric intake, triglyceride concentration, fasting 
glucose concentration, fasting insulin concentration, and 
glucose AUC following an oral glucose challenge.  For 
each variable, the change in pre- Rapa dose value to 
post- Rapa dose value, measured following (one month) 
of dosing was compared for control subjects versus 
rapamycin-treated subjects in a two-way, repeated 
measures ANOVA.  An additional repeated measures 
ANOVA was used to compare values within each 
rapamycin-treated subject over time for the entire 
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dosing period.  Comparisons of tissue protein activity 
were done using MANOVA with Bonferroni 
corrections. Analyses were conducted using GraphPad/ 
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